Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.

[This corrects the article DOI: 10.21037/tlcr-21-682.]. 2022 Translational Lung Cancer Research. All rights reserved.

The article (1) titled “Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer” (doi: 10.21037/tlcr-21-682), unfortunately contained a mistake in the first affiliation of Zhen Wang1,2 and Yong Song1,5#. The correct authors’ affiliation 1 is listed below:

1The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.

Therefore, the correct author information is as follows:

Zhen Wang1,2, Lingyun Wei3, Jing Li2, Han Zhou2, Si Li4, Dongsheng Chen4, Yangyang Yu4, Lele Zhao4, Xixu Zhu2#, Yong Song1,5#

1The First School of Clinical Medicine, Southern Medical University, Guangzhou, China; 2Department of Radiation Oncology, Jinling Hospital, Nanjing, China; 3Department of Cardiothoracic Surgery, School of Medicine, Nanjing University/General Hospital of Eastern Theater Command, Nanjing, China; 4The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China; 5Department of Respiratory and Critical Care Medicine, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing, China

The authors regret the error.

Click here to view the updated version of the article.